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The Chernobyl accident led to the increase in 
thyroid cancer incidence in Ukraine. There is also a 
rise in anaplastic thyroid carcinoma (ATC), which is a 
relatively rare (1–10% of all malignant thyroid tumors) 
yet one of the most aggressive types of human cancer 
with an extremely poor prognosis [1, 2].
Taxol (paclitaxel, docetaxel) is an anticancer drug, 
successfully used for treatment of lung, breast, ova­
rian, head and neck cancer [3]. Attempts are made to 
extend the range of malignancies that could be treated 
by Taxol, including anaplastic thyroid cancer [4, 5]. 
To increase Taxol efficacy, it is essential to under­
stand fine biochemical changes induced by the drug 
in thyroid cancer cells. Taxol is well known to cause 
microtubules hyperpolymerization that in turn results in 
cell cycle alterations [3, 6] but the detailed mechanisms 
of its effects on cell cycle machinery are still unclear.
The peptidyl­prolyl cis/trans isomerase Pin1, a mem­
ber of the parvulin family of peptidyl­prolyl isomerases, 
specifically binds phosphorylated Ser/Thr­Pro motifs 
and catalyzes the cis/trans isomerization of the peptide 
bond. Various transcription factors and regulators have 
been identified as substrates for Pin1. It enhances AP­1 
activity through isomerization of both c­Jun and c­Fos 
and stabilizes the tumor suppressors p53 and p73 [7]. 
Pin1 overexpression in human cancers is important 
for the activation of multiple oncogenic pathways. Its 
deletion suppresses the ability of certain oncogenes 
to induce cancer in mice [8, 9]. Pin1 has been recently 
implicated in cell cycle control. It affects cyclin D1 and 
cyclin E, c­Myc, p53 and p73 expression and stability, 
interacts with a series of mitotic phosphoproteins, in­
cluding Plk1, Cdc25 [10], Wee1 [11], and, possibly, the 
pRb/E2F complexes [12]. 
In human prostate cancer cells Pin1 mediates 
Taxol­induced apoptosis via modulation of phospho­
rylated Bcl­2 [13] but exact mechanisms of drug­
induced apoptosis and cell cycle perturbations remain 
obscure.
This study was set out to clarify the mechanisms of 
Taxol effects on the early stages (G1/S transition) of cell 
cycle in human ATC cell lines ARO and KTC­2. 
MATERIALS AND METHODS
Cell lines and conditions of culturing. Human 
ATC cell line ARO were initially provided by J.A. Fagin 
(Memorial Sloan­Kettering Cancer Center, New York, 
NY, USA). KTC­2 cell line was established at Kawasaki 
Medical School (Okayama, Japan). 
Cells were grown in RPMI 1640 medium supple­
mented with 5% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (all reagents from Invitrogen 
Life Technologies, Paisley, UK) in a 5% CO2 humidified 
atmosphere at 37 °C. After 2 days incubation, when 
the culture reached about 80% confluence, cells were 
washed twice with phosphate­buffered saline (PBS) 
(pH 7.4) at 37 °C, and a fresh medium was added to 
each dish. Cells were incubated for an additional 24 h, 
exposed to the drug as described below, and then 
collected at different time intervals.
Preparation of cell extracts. Cells were washed 
twice with an ice­cold PBS supplemented with sodium 
pyrophosphate and orthovanadate, scraped with a 
rubber policeman, collected in 1 ml PBS, and cen­
trifuged for 3 min at 1000 rpm at 4 °C. The pellet was 
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then resuspended in 200 µl of the lysis buffer (Cell 
Signaling Technology, USA) containing a cocktail of 
protease and phosphatase inhibitors. After 15 min on 
ice, lysates were centrifuged for 15 min at 15,000 g 
and stored at –80 °C until use. Protein concentration 
was determined with bicinchoninic acid assay reagent 
kit (Sigma, St. Louis, MO, USA) according to manu­
facturer’s protocol.
Western blotting. Total cell lysates were boiled 
in the sample buffer (100 mM Tris­HCl, 4% sodium 
dodecyl sulfate, 0.2% bromophenol blue, 20% gly­
cerol, 10% dithiothreitol) and resolved in 7.5–15% 
gradient SDS­PAGE gels (Biocraft, Tokyo, Japan). 
The single 8% and 15% acrylamide concentration 
gels were used when better separation of high­ and 
low­molecular weight proteins, respectively, was re­
quired. 40 µg of total protein were applied per each 
lane. Proteins were transferred onto 0.2­µm nitrocel­
lulose membranes (Millipore Corp., Bedford, MA, USA) 
by semi­dry blotting. Membranes were blocked with 
Tris­buffered saline / 0.1% Tween 20 containing 5% 
nonfat dry milk and incubated with primary antibodies 
(Pin1, phospho­pRb, phospho­c­Abl, phospho­CHK1, 
PARP, rapamicin, р27KIP1, p21WAF1 were from Cell Signa­
ling Technolo gy, USA; phospho­p53, β­actin — from 
Santa Cruz Biotechnology, USA) at 4 °C overnight. After 
washing three times with Tris­buffered saline / 0.1% 
Tween­20, the blots were incubated with horseradish 
peroxidase­conjugated species­specific secondary 
antibody (Cell Signaling Technology) for 1 h at room 
temperature and then again washed three times. Com­
plexes were visualized using ECL reagents (Amersham, 
Arlington Heights, USA) in a LAS­3000 imaging system 
(Fujifilm, Tokyo, Japan). 
Statistical analysis. All data were expressed 
as a mean ± SE. Differences between groups were 
examined for statistical significance using Student’s 
t test. P < 0.05 denoted the presence of a statistically 
significant difference.
RESULTS AND DISCUSSION
Taxol effects on early cell cycle events. Cell 
entry into the S­phase of cell cycle (DNA replication) 
starts with mitogen/c­Myc­induced phosphorylation 
of the retinoblastoma protein (pRb) and that of two 
members of pocket protein family, р107 and р130, 
by the cyclin/CDK complexes, namely by the cyclin 
D/CDK4/6 ([14], for review). As a result, pRb affinity 
to the E2F transcription factor family, which play a key 
role in G1/S transition, decreases and released E2F 
upregulates the expression of the cyclin E and cyclin 
A genes. Next, the cyclin E/CDK2 complex phospho­
rylates other amino acid residues pRb. Thus, pRb 
phosphorylation results in transcription initiation and 
accumulation of cyclins, CDKs and of other factors 
promoting cell cycle and determining the checkpoint­1 
transition and entrance to S­phase [14].
In ARO and KTC­2 cells exposed to low doses of 
Taxol (15–25 nM), which cause bona fide apoptosis [5], 
the enhancement of pRb phosphorylation on Ser795 
and Ser807/811 residues was observed (Fig. 1 (1) and 
1 (2)). Phosphorylation of Ser795 was registered after 
6 h of cell exposure to Taxol whereas that of Ser807/811 
after 12 h incubation. Perhaps these modifications take 
place successively and comprise the initial events of 
Rb phosphorylation. The maximal phosphorylation of 
both sites was observed at 24 h followed by a slight 
decrease at 36 h (see Fig. 1 (1) and 1 (2)). Such inten­
sive modifications may represent the dissociation of 
pRb/E2F and activation of the E2F/DNA­polymerase 
complexes under these conditions. The c­Myc level in 
untreated cell was rather high, as it is in most human 
cancers [15]. In ATC cells, further c­Myc accumulation 
was seen only after 36 h of cell incubation with Taxol 
(Fig. 1 (6)).
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Fig. 1. Effects of Taxol on cell cycle regulatory and apoptosis­
related proteins. 1–7 — time course of Taxol (25 nM) effects on 
protein expression and phosphorylation; 8–9 — effect of different 
Taxol concentration on Pin1 expression after 36 h of cell exposure 
to the drug. 10 — effect of rapamycin on Taxol­induced PARP 
cleavage. Arrows show the position of intact PARP (116 kDa) 
and its larger fragment (89 kDa). Results are representative of 
least two experiments
In both cell lines, after 6 h of treatment with Taxol 
we observed, simultaneously with pRb phosphoryla­
tion, the decrease in the level of a CDK inhibitor and 
thus the negative regulator of G1/S transition, p27
KIP1 
(Fig. 1 (3)). It possibly occurs as a result of prote­
osomal degradation after p27KIP1 phosphorylation by 
the cyclin E/CDK2 complex [14]. Degradation of р27KIP1 
that binds and suppresses the cyclin E/CDK2 and cy­
clin A/CDK2 complexes, which play an important role 
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in the late G1­ and S­phases, creates the conditions for 
transition through these stages of cell cycle.
In contrast to р27KIP1, the level of another key CDK 
inhibitor, p21WAF1, increased during the first hours of 
cell incubation with Taxol. It decreased significantly 
only after 12 h of incubation with the drug (Fig. 1 (4)). 
This probably can be explained by the differential 
temporal roles of p21WAF1. At the early stages of cell 
cycle it stabilizes and promotes cyclin D/CDK4/6 
translocation to nucleus ([16], for review) while after 
the breakdown of these complexes p21WAF1 manifests 
its inhibitory properties on the cyclin E/CDK2 and 
cyclin A/CDK2 complexes. 
We also did not observe checkpoint kinase CHK1 
phosphorylation, i. e. activation (data not shown), 
which is required for cell cycle arrest [17].
Thus, Taxol at low concentrations, on the one 
hand, enhanced pRb phosphorylation that causes the 
release of transcription factor E2F. On the other hand, 
it did not activate CHK1 and decreased the levels of 
G1/S transition inhibitors, р27
KIP1 and p21WAF1. Taken 
together, these findings suggest that Taxol displays 
a mitogen­like effect by stimulating the initial stages 
of cell cycle in ATC cells. The significance of such 
stimulation is unclear, but one can expect that cell 
cycle progression is a necessary condition of Taxol­
induced apoptosis [5, 18]. Our data showed that low 
concentrations of Taxol, which initiated true apoptosis 
in ATC cells, did not arrest cell cycle [5]. High concen­
trations of the drug (100–1000 nM) do arrest cell cycle 
in G2/M phase and induce mitochondrial collapse and 
necrosis­like death in ATC cells [5]. 
The role of peptidyl-prolyl cis/trans isomerase 
Pin1 in Taxol-dependent apoptosis. Pin1 is one of 
the key cell cycle regulators [19], but its role in apop­
tosis, cell proliferation and survival is still controversial. 
Some reports have claimed proapoptotic effects of 
Pin1 [20–22], while others described its involvement 
in cell survival and oncogenesis [23–25]. 
A growing body of evidence indicates that Pin1 
plays a major role in the G0/G1/S transition, and its 
levels in normal cells are significantly elevated at the 
G1/S phase [19, 26]. Pin1 is also overexpressed and 
positively regulates cyclin D1 by transcriptional activa­
tion and posttranslational stabilization in breast [26, 
27] and thyroid tumors [28].
Fig. 1 (7) and 2 (1) shows that Taxol caused the 
increase of Pin1 level in ATC cells. Notably, the mode of 
Pin1 expression resembled that of c­Myc (Fig. 1 (6)). 
In ARO cells, the level of Pin1 was rather high in cont­
rol and increased at low Taxol doses (Fig. 1 (8) and 
2 (2)). At apoptotic concentration of Taxol (25 nM), 
the expression of Pin1 was maximal with subsequent 
sharp decrease at higher drug concentrations (100 
or 1000 nM). In KTC­2 cells Taxol induced a slight ac­
cumulation of Pin1, which also dropped dramatically 
at higher Taxol doses (Fig. 1 (9)). 
Pin1 is known to activate a tumor suppressor p53 
and other proteins of p53 family, in particular p73 [29]. 
In response to DNA damage p53/p73 are phosphory­
lated by c­Abl, p38MAPK and other protein kinases on 
Ser and Thr residues that allow the interaction of p73 
with Pin1. The latter catalyzes prolyl isomerization and 
results in conformational changes, acetylation, stabi­
lization, and functional activation of p73 [29]. In KTC­2 
cells Taxol stimulated phosphorylation of both c­Abl 
(data not shown) and p53 (Fig. 1 (5)). p53 activation 
in response to genotoxic or other stress, depending 
on strength of such challenge, may generally cause 
two different effects: cell cycle arrest or apoptosis. 
p21WAF1 is an antiapoptotic factor and its decrease (see 
Fig. 1 (4)) may sensitize cells to apoptosis [30]. Thus, 
it is possible that Pin1 could act as a p53 stabilizer 
thereby activating p53­dependent apoptotic pathway. 
In ARO cells, which carry mutant TP53 gene, Pin1 
could stabilize a structural and functional homolog 
of p53, p73. p73 is highly expressed in a significant 
proportion of anaplastic thyroid cancers whereas 
it is undetectable in normal thyroid epithelium or in 
papillary and follicular thyroid cancer cells [31]. It is 
noteworthy that maximal expression of Pin1 coincides 
with most efficient proapoptotic Taxol concentration 
[5], and that rapamycin, a clinically important antibio­
tic and immunosuppressant, which also inhibits Pin1 
and other peptidyl­prolyl cis/trans isomerases [32], 
significantly suppressed Taxol­induced poly(ADP­
ribose)­polymerase (PARP) cleavage, a hallmark of 
apoptosis (Fig. 1 (10)). Pin1 can directly participate 
in Taxol­dependent apoptosis by preserving drug­
induced Bcl­2 phosphorylation [5, 13].
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Fig. 2. Dependence of Pin1 accumulation on Taxol concentration 
and time of cells exposition to the drug. 1 — time course of Taxol 
(25 nM) effects on Pin1 expression in ARO cells. Figures on the 
plot columns show P value; 2 — effect of Taxol concentration on 
Pin1 content in ARO cells. **P < 0.01; n = 3.
It is interesting that at high Taxol concentrations, 
at which the drug is likely to cause forms of cell 
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death other then apoptotic, Pin1 level was drastically 
decreased (Fig. 1 (8) and 1 (9)). Exact mechanisms 
and significance of such decrease are not clear at a 
moment. It is known that Pin1 stimulates cell cycle 
transition by increasing cyclin D expression, through 
activation of a key phosphatase cdc25C and inhibition 
of Wee1 kinase. Together these changes result in the 
activation of the cyclin B/cdc2 — the main G2/M driving 
complex [11, 19]. Our data imply that Taxol­dependent 
decrease of Pin1 could be a reason for G2/M cell cycle 
arrest caused by the drug.
Overall, the results presented here indicate that 
Taxol at low, apoptotic concentrations exhibited 
mitogen­like properties, facilitating G1/S cell cycle 
transition in anaplastic thyroid cancer cells. Moreover, 
low doses of Taxol increased Pin1 expression, which 
could be involved in drug­induced apoptosis via the 
p53/p73­dependent mechanism. In addition, the 
increased Pin1 level can probably promote cell cycle 
transition. Finally, we demonstrated that high Taxol 
doses resulted in a dramatic reduction of Pin1 level that 
may represent the mechanism by which Taxol induces 
G2/M cell cycle arrest. 
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РАЗЛИЧИЕ ЭФФЕКТОВ НИЗКИХ И ВЫСОКИХ ДОЗ ТАКСОЛА 
В КЛЕТКАХ АНАПЛАСТИЧЕСКОГО РАКА ЩИТОВИДНОЙ 
ЖЕЛЕЗЫ: ВОЗМОЖНОЕ УЧАСТИЕ ПРОЛИЛ-ИЗОМЕРАЗЫ PIN1
Цель: изучить молекулярный механизм дозозависимых эффектов противоопухолевого препарата таксола на клеточный цикл и 
ассоциированные с апоптозом белки в клетках линий ARO и KTC-2 анапластического рака щитовидной железы. Материалы 
и методы: для количественного анализа содержания различных белков и их фосфорилированных форм использовали Вестерн 
блоттинг. Результаты: при действии таксола в дозе 25 нмоль/л, которая вызывает апоптоз клеток ARO и KTC-2, отмечается 
усиление фосфорилирования белка Rb, снижение экспрессии ингибиторов циклинзависимых киназ р27KIP1 и p21WAF1, а также 
накопление фосфорилированного р53 и пролил-изомеразы Pin1. Высокие дозы таксола (100 и 1000 нмоль/л), вызывающие 
некрозоподобную гибель клеток, заметно снижают уровень Pin1 в обеих клеточных линиях. Выводы: низкие дозы таксола 
способствуют переходу из G1 в S-фазу клеточного цикла, что свидетельствует о митогенподобном действии препарата. Инду-
цированное таксолом накопление изомеразы Pin1, возможно, облегчает этот переход и параллельно участвует в апоптотических 
процессах через p53/p73-зависимый механизм. При более высоких дозах препарата отмечают существенное снижение уровня 
Pin1, что может быть одной из причин задержки клеточного цикла на стадии G2/M.
Ключевые слова: таксол, анапластический рак щитовидной железы, клеточный цикл, пролил-изомераза Pin1, апоптоз.
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